Tumor markers and treatments for Kaposi sarcoma

AIDS

Volumn 21, Issue 12, 2007, Pages 1637-1639

  Anderson, Lesley A ^a   Goedert, James J ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

Africa; Antiviral therapy; Cancer chemotherapy; HIV AIDS; Human herpesvirus 8; Kaposi sarcoma; Transplantation; Virus load

Indexed keywords

CIDOFOVIR; FOSCARNET; GANCICLOVIR; TUMOR MARKER;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER CHEMOTHERAPY; COMORBIDITY; DISEASE ASSOCIATION; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; NOTE; PRIORITY JOURNAL; VIREMIA; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HERPESVIRUS 8, HUMAN; HIV INFECTIONS; HUMANS; SARCOMA, KAPOSI; TUMOR MARKERS, BIOLOGICAL; VIRAL LOAD;

EID: 34447576403     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32826fb721     Document Type: Note

References (35)

1. Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20:1645-1654.
2. Wabinga HR, Parkin DM, Wabwire-Mangen F, Mugerwa JW. Cancer in Kampala, Uganda, in 1989-91: changes in incidence in the era of AIDS. Int J Cancer 1993; 54:26-36.
3. Chokunonga E, Levy LM, Bassett MT, Mauchaza BG, Thomas DB, Parkin DM. Cancer incidence in the African population of Harare, Zimbabwe: second results from the cancer registry 1993-1995. Int J Cancer 2000; 85:54-59.
4. Nasti G, Martellotta F, Berretta M, Mena M, Fasan M, Di Perri G, et al. Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome-related Kaposi sarcoma. Cancer 2003; 98:2440-2446.
5. Nasti G, Talamini R, Antinori A, Martellotta F, Jacchetti G, Chiodo F, et al. AIDS-related Kaposi's sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era-the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals. J Clin Oncol 2003; 21:2876-2882.
6. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266:1865-1869.
7. Whitby D, Howard MR, Tenant-Flowers M, Brink NS, Copas A, Boshoff C, et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma [see comments]. Lancet 1995; 346:799-802.
8. Brown EE, Whitby D, Vitale F, Marshall V, Mbisa G, Gamache C, et al. Virologic, hematologic and immunologic risk factors for classic Kaposi sarcoma. Cancer 2006; 107:2282-2290.
9. Boneschi V, Brambilla L, Berti E, Ferrucci S, Corbellino M, Parravicini C, et al. Human herpesvirus 8 DNA in the skin and blood of patients with Mediterranean Kaposi's sarcoma: clinical correlations. Dermatology 2001; 203:19-23.
10. Pellet C, Kerob D, Dupuy A, Carmagnat MV, Mourah S, Podgorniak MP, et al. Kaposi's sarcoma-associated herpesvirus viremia is associated with the progression of classic and endemic Kaposi's sarcoma. J Invest Dermatol 2006; 126: 621-627.
11. Pellet C, Chevret S, Frances C, Euvrard S, Hurault M, Legendre C, et al. Prognostic value of quantitative Kaposi sarcoma-associated herpesvirus load in posttransplantation Kaposi sarcoma. J Infect Dis 2002; 186:110-113.
12. Quinlivan EB, Zhang C, Stewart PW, Komoltri C, Davis MG, Wehbie RS. Elevated virus loads of Kaposi's sarcoma-associated human herpesvirus 8 predict Kaposi's sarcoma disease progression, but elevated levels of human immunodeficiency virus type 1 do not. J Infect Dis 2002; 185:1736-1744.
13. Martro E, Cannon MJ, Dollard SC, Spira TJ, Laney AS, Ou CY, et al. Evidence for both lytic replication and tightly regulated human herpesvirus 8 latency in circulating mononuclear cells, with virus loads frequently below common thresholds of detection. J Virol 2004; 78:11707-11714.
14. Laney AS, Dollard SC, Jaffe HW, Offermann MK, Spira TJ, Gunthel CJ, et al. Repeated measures study of human herpesvirus 8 (HHV-8) DNA and antibodies in men seropositive for both HHV-8 and HIV. AIDS 2004; 18:1819-1826.
15. Little RF, Merced-Galindez F, Staskus K, Whitby D, Aoki Y, Humphrey R, et al. A pilot study of cidofovir in patients with Kaposi sarcoma. J Infect Dis 2003; 187:149-153.
16. Dupon M, Masquelier B, Cazorla C, Chene G, Dumon B, Ragnaud JM, et al. Acquired immunodeficiency syndrome-associated Kaposi's sarcoma and human herpesvirus 8 DNA detection in serial peripheral blood mononuclear cell samples. Res Virol 1997; 148:417-425.
17. Engels EA, Biggar RJ, Marshall VA, Walters MA, Gamache CJ, Whitby D, et al. Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-associated Kaposi's sarcoma. AIDS 2003; 17:1847-1851.
18. Laney AS, Cannon MJ, Jaffe HW, Offermann MK, Ou CY, Radford KW, et al. Human herpesvirus 8 (HHV-8) presence and viral load are associated with changes in Kaposi's sarcoma severity among HIV-positive men. AIDS 2007; 21:00-00.
19. Pellet C, Chevret S, Blum L, Gauville C, Hurault M, Blanchard G, et al. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy. J Invest Dermatol 2001; 117:858-863.
20. Cannon MJ, Dollard SC, Black JB, Edlin BR, Hannah C, Hogan SE, et al. Risk factors for Kaposi's sarcoma in men seropositive for both human herpesvirus 8 and human immunodeficiency virus. AIDS 2003; 17:215-222.
21. Casper C. Defining a role for antiviral drugs in the treatment of persons with HHV-8 infection. Herpes 2006; 13:42-47.
22. Klass CM, Offermann MK. Targeting human herpesvirus-8 for treatment of Kaposi's sarcoma and primary effusion lymphoma. Curr Opin Oncol 2005; 17:447-455.
23. Krown SE. Therapy of AIDS-associated Kaposi's sarcoma: targeting pathogenetic mechanisms. Hematol Oncol Clin North Am 2003; 17:763-783.
24. Martin DF, Kuppermann BD, Wolitz RA, Palestine AG, Li H, Robinson CA. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group [see comments]. N Engl J Med 1999; 340:1063-1070.
25. Krown SE. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. J Clin Oncol 2004; 22:399-402.
26. Cattelan AM, Calabro ML, Gasperini P, Aversa SM, Zanchetta M, Meneghetti F, et al. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome. J Natl Cancer Inst Monogr 2001; (28):44-49.
27. Bourboulia D, Aldam D, Lagos D, Allen E, Williams I, Cornforth D, et al. Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia. AIDS 2004; 18:485-493.
28. Gill J, Bourboulia D, Wilkinson J, Hayes P, Cope A, Marcelin AG, et al. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma-associated herpesvirus infection in patients with and without Kaposi sarcoma. J Acquir Immune Defic Syndr 2002; 31:384-390.
29. Cattelan AM, Calabro ML, De Rossi A, Aversa SM, Barbierato M, Trevenzoli M, et al. Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy. Int J Oncol 2005; 27:779-785.
30. Martin-Carbonero L, Barrios A, Saballs P, Sirera G, Santos J, Palacios R, et al. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS 2004; 18:1737-1740.
31. Vaccher E, di Gennaro G, Simonelli C, Schioppa O, Tirelli U. Evidence of activity of Irinotecan in patients with advanced AIDS-related Kaposi's sarcoma. AIDS 2005; 19:1915-1916.
32. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352:1317-1323.
33. International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15:594-603.
34. Fizazi K, Culine S, Kramar A, Amato RJ, Bouzy J, Chen I, et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol 2004; 22:3868-3876.
35. Vaena DA, Abonour R, Einhorn LH. Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables. J Clin Oncol 2003; 21:4100-4104.